

Abiraterone

Section	Indications
Hormones and antihormones Oral > Solid: 250 mg; 500 mg	Malignant neoplasms of prostate

Anastrozole

Section	Indications
Hormones and antihormones Oral > Solid: 1 mg tablet	Other specified malignant neoplasms of breast Malignant neoplasms of breast

Bicalutamide

Section	Indications
Hormones and antihormones Oral > Solid: 50 mg	Malignant neoplasms of prostate

Dexamethasone

Section	Indications
Hormones and antihormones Oral > Solid: 4 mg Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt) Oral > Liquid: 2 mg per 5 mL Oral > Solid: 2 mg; 4 mg	Plasma cell myeloma Lymphoid leukaemia, not elsewhere classified Burkitt lymphoma including Burkitt leukaemia

Enzalutamide

Section	Indications
Hormones and antihormones Oral > Solid: 40 mg	Therapeutic equivalent to abiraterone for Malignant neoplasms of prostate Malignant neoplasms of prostate

Flutamide

Section

Hormones and antihormones

Indications

Therapeutic equivalent to bicalutamide for

Malignant neoplasms of prostate

Fulvestrant

Section

Hormones and antihormones

Parenteral > General injections > IV: 250 mg per 5 mL

Indications

Malignant neoplasms of breast

Goserelin

Section

Hormones and antihormones

Indications

Therapeutic equivalent to leuporelin for

Malignant neoplasms of breast

Therapeutic equivalent to leuporelin for

Malignant neoplasms of prostate

Hydrocortisone

Section

Hormones and antihormones

Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)

Indications

Lymphoid leukaemia, not elsewhere classified

Unspecified malignant neoplasms of ill-defined or unspecified sites

Burkitt lymphoma including Burkitt leukaemia

Leuporelin

Section

Hormones and antihormones

Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe

Indications

Malignant neoplasms of breast

Malignant neoplasms of prostate

Methylprednisolone

Section

Hormones and antihormones

Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)

Indications

Lymphoid leukaemia, not elsewhere classified

Burkitt lymphoma including Burkitt leukaemia

Nilutamide

Section

Hormones and antihormones

Indications

Therapeutic equivalent to bicalutamide for

Malignant neoplasms of prostate

Prednisolone

Section

Hormones and antihormones

Oral > Liquid: 5 mg per mL

Oral > Solid: 5 mg; 25 mg

Indications

Unspecified malignant neoplasms of ill-defined or unspecified sites

Plasma cell myeloma

Follicular lymphoma

Lymphoid leukaemia, not elsewhere classified

Malignant neoplasms of prostate

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Hodgkin lymphoma

Diffuse large B-cell lymphomas

Burkitt lymphoma including Burkitt leukaemia

Prednisone

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [prednisolone](#) for

Plasma cell myeloma

Therapeutic equivalent to [prednisolone](#) for

Follicular lymphoma

Therapeutic equivalent to [prednisolone](#) for

Lymphoid leukaemia, not elsewhere classified

Therapeutic equivalent to [prednisolone](#) for

Malignant neoplasms of prostate

Therapeutic equivalent to [prednisolone](#) for

Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Therapeutic equivalent to [prednisolone](#) for

Hodgkin lymphoma

Therapeutic equivalent to [prednisolone](#) for

Diffuse large B-cell lymphomas

Tamoxifen

Section

Hormones and antihormones

Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)

Indications

Other specified malignant neoplasms of breast

Malignant neoplasms of breast

Triptorelin

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [leuprorelin](#) for

Malignant neoplasms of breast

Therapeutic equivalent to [leuprorelin](#) for

Malignant neoplasms of prostate